AGLE-102
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase 1/2Active
Key Facts
Indication
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase
Phase 1/2
Status
Active
Company
About Aegle Therapeutics
Aegle Therapeutics is a private, clinical-stage biotech founded in 2015 and based in Miami, Florida, operating in the biologics sector. The company is developing a novel therapeutic platform based on extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs), with its lead program AGLE-102 in a Phase 1/2 trial for Recessive Dystrophic Epidermolysis Bullosa (RDEB). Aegle's technology aims to leverage the inherent signaling and cargo-delivery functions of EVs to treat rare diseases with high unmet need, positioning it at the forefront of the emerging EV therapeutics field. The company is currently pre-revenue and focused on advancing its clinical pipeline.
View full company profileTherapeutic Areas
Other Recessive Dystrophic Epidermolysis Bullosa (RDEB) Drugs
| Drug | Company | Phase |
|---|---|---|
| ABCB5+ MSCs (systemic) | RHEACELL | Phase III |